Skip to main content
GutCited

베르베린 관련 소장 세균 과증식(SIBO)

C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.

후향적 연구에서 베르베린을 포함한 허브 항균 프로토콜이 SIBO에서 리팍시민과 유사한 효능을 보였습니다. 전향적 RCT 자료는 제한적입니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dsibo'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            C

        

        

            
결론

            
            
후향적 연구에서 베르베린을 포함한 허브 항균 프로토콜이 SIBO에서 리팍시민과 유사한 효능을 보였습니다. 전향적 RCT 자료는 제한적입니다.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Meta-Analysis
                
                
                n=1552
                
                
                
            

            
                Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
            
            

                
                Dose: None
                
                
                vs: Multiple comparators (network meta-analysis)
                
                
                Outcome: SIBO eradication rate
                
                
                효과: Berberine highest SUCRA
                
                
                None
                
            

            
            
대상 집단: Adults with SIBO from 30 RCTs

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                2 weeks
                
                
                Open-label
                
            

            
                Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, …
            
            

                
                Dose: 400 mg d
                
                
                vs: control
                
                
                Outcome: a negative breath test
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: Long-term abdominal discomfort and avoiding excessive examination

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
2

        
연구

    

    

        
180

        
참여자

    

    

        
            
            ↑
            
        
        
Positive

    

    

        C

        
등급

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Therapeutic advances in …
                        2025
                        
                    

                

                
                

                    

                        
                            Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Frontiers in pharmacology
                        2023
                        
                        8 인용
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
일반적으로 사용되는 용량

                

                    
                    

                        
general:

                        
500-1,500 mg/day in divided doses

                    

                    
                    

                        
siboprotocol:

                        
500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)

                    

                    
                    

                        
giantimicrobial:

                        
500 mg twice daily

                    

                    
                

                
                

                    상한량: Generally well-tolerated up to 1,500 mg/day in divided doses
                

                
            

            

            
            

                
연구에서 사용된 용량

                

                    

                        
                            

                                용량
                                기간
                                효과
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                1552
                            

                            
                            

                                400 mg d
                                2 weeks
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                권장 복용 시간: With meals; divide doses throughout the day (do not take full daily dose at once)
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
보고된 부작용

                    
    
                        
                        
  • 
                            ⚠
                            GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
                        
    • 
                        
                        
  • 
                            ⚠
                            May cause uterine contractions (contraindicated in pregnancy)
                        
    • 
                        
                        
  • 
                            ⚠
                            Headache
                        
    • 
                        
                        
  • 
                            ⚠
                            Skin rash (rare)
                        
    • 
                        
                    

                

                

                
                

                    
알려진 상호작용

                    
    
                        
                        
  • 
                            ●
                            Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
                        
    • 
                        
                        
  • 
                            ●
                            Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
                        
    • 
                        
                        
  • 
                            ●
                            Anticoagulants (may have additive blood-thinning effects)
                        
    • 
                        
                        
  • 
                            ●
                            Metformin (additive glucose-lowering effect; monitor closely)
                        
    • 
                        
                        
  • 
                            ●
                            Macrolide antibiotics (berberine inhibits CYP3A4)
                        
    • 
                        
                    

                

                

                
                

                    

                        일일 최대 섭취 허용량: Generally well-tolerated up to 1,500 mg/day in divided doses
                    

                

                
            

            

                건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does 베르베린 help with 소장 세균 과증식(SIBO)?
            
        
        

            Based on 2 studies with 180 participants, there is limited but promising evidence that 베르베린 may support 소장 세균 과증식(SIBO) management. Our evidence grade is C (Some Evidence).
        

    

    
    

        
            How much 베르베린 should I take for 소장 세균 과증식(SIBO)?
            
        
        

            Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of 베르베린?
            
        
        

            Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for 베르베린 and 소장 세균 과증식(SIBO)?
            
        
        

            We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 180 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  




            

                
                

                    
관련 다른 성분: 소장 세균 과증식(SIBO)

                    

                        
                        
                            부분가수분해 구아검(PHGG)
                            C

                        
                        
                    

                

                

                
                

                    
베르베린 다른 건강 상태에 대한 근거

                    

                        
                        
                            급성 설사
                            C

                        
                        
                        
                            장내 미생물 불균형(디스바이오시스)
                            D

                        
                        
                    

                

                
            

        

        

    


    
    






  
References

  
    
    
    
  1. 
      [1]
      Qinlin Zhang et al..
      Therap Adv Gastroenterol.
      2025.
      Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
      doi:10.1177/17562848251399033
      PubMed
    
    2. 
    
    
  2. 
      [2]
      Huaizhu Guo et al..
      Front Pharmacol.
      2023.
      Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO …
      doi:10.3389/fphar.2023.1121435
      PubMed
    
    3. 
    
  















    

        FDA 면책 조항:
        이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.